More Cohesive Coverage-With-Evidence Authority Needed, Lawmakers Told
This article was originally published in The Gray Sheet
Former CMS coverage chief Louis Jacques told House lawmakers that the agency’s authorities to implement coverage-with-evidence-development policies are fragmented, hindering application of the program.
You may also be interested in...
In the first part of a two-part Q&A, just-departed CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
Activities by Medicare contractors were among several matters that were addressed in CMS’ recent CED draft guidance that may not be fully clarified until the updated guidelines are put into practice, experts say.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.